Posted by Michael Wonder on 03 Jul 2019
FDA accepts new drug application for INSYS Therapeutics’ naloxone nasal spray for the emergency treatment of known or suspected opioid overdose
3 July 2019 - INSYS Therapeutics announced today that its new drug application to the U.S. FDA for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and paediatric patients has been accepted for filing.
INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8 mg naloxone dose.
